Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Supko · SciRah

Researcher profile · Semantic Scholar

J. Supko

Share profile

J. Supko — researcher profile on SciRah

h-index: 51
Works: 247
Citations: 12K

Most-cited papers

A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme
M. Rosenfeld, Xiao-Bu Ye, J. Supko, S. Desideri +16 more
2014Autophagy497 citations Open access
Semantic Scholar
Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia
D. DeAngelo, K. Stevenson, S. Dahlberg, L. Silverman +18 more
2014Leukemia314 citations Open access
Semantic Scholar
Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
L. Vrooman, K. Stevenson, J. Supko, Jane E. O'Brien +15 more
2013Journal of Clinical Oncology292 citations Open access
Semantic Scholar
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib
N. Wagle, B. Grabiner, E. V. Van Allen, Eran Hodis +18 more
2014Cancer Discovery284 citations Open access
Semantic Scholar
A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
D. Hong, R. Kurzrock, J. Supko, Xiao-Ying He +14 more
2012Clinical Cancer Research235 citations Open access
Semantic Scholar
Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
A. Place, K. Stevenson, L. Vrooman, M. Harris +19 more
2015The Lancet Oncology220 citations
Semantic Scholar
Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma
D. Vogl, N. Raje, S. Jagannath, P. Richardson +9 more
2017Clinical Cancer Research207 citations Open access
Semantic Scholar
Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials.
B. Albrecht, Victor S. Gehling, M. Hewitt, Rishi G. Vaswani +23 more
2016Journal of Medicinal Chemistry183 citations Open access
Semantic Scholar
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
Andrew J. Yee, W. Bensinger, J. Supko, P. Voorhees +12 more
2016The Lancet Oncology182 citations Open access
Semantic Scholar
A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small Cell Lung Cancer
S. Goldberg, J. Supko, J. Neal, A. Muzikansky +10 more
2012Journal of Thoracic Oncology157 citations Open access
Semantic Scholar
Acoustic feedback enables safe and reliable carboplatin delivery across the blood-brain barrier with a clinical focused ultrasound system and improves survival in a rat glioma model
N. McDannold, Yong-Zhi Zhang, J. Supko, Chanikarn Power +5 more
2019Theranostics117 citations Open access
Semantic Scholar
Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial
Ran Xu, F. Shimizu, Koos E Hovinga, K. Beal +21 more
2016Clinical Cancer Research111 citations Open access
Semantic Scholar
Tumor suppression by small molecule inhibitors of translation initiation
Limo Chen, B. Aktas, Yibo Wang, Xiao-Ying He +10 more
2012OncoTarget102 citations Open access
Semantic Scholar
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
D. Peereboom, M. Ahluwalia, Xiao-Bu Ye, J. Supko +6 more
2013Neuro-Oncology94 citations Open access
Semantic Scholar
Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
W. Salzer, B. Asselin, J. Supko, M. Devidas +7 more
2013Blood79 citations Open access
Semantic Scholar
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001
L. Vrooman, T. Blonquist, K. Stevenson, J. Supko +18 more
2021Journal of Clinical Oncology70 citations
Semantic Scholar
Efficacy, safety, pharmacokinetics and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: A phase II study
A. Zhu, M. Ancukiewicz, J. Supko, D. Sahani +14 more
2013Clinical Cancer Research68 citations Open access
Semantic Scholar
Phase I study of terameprocol in patients with recurrent high-grade glioma.
S. Grossman, Xiao-Bu Ye, D. Peereboom, M. Rosenfeld +3 more
2012Neuro-Oncology60 citations Open access
Semantic Scholar
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas
M. Holdhoff, Xiao-Bu Ye, J. Supko, L. Nabors +12 more
2017Neuro-Oncology51 citations Open access
Semantic Scholar
Phase I Study of RO4929097 with Bevacizumab in Patients with Recurrent Malignant Glioma
Edward Pan, J. Supko, T. Kaley, N. Butowski +6 more
2016Journal of Neuro-Oncology47 citations Open access
Semantic Scholar
A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial
D. DeAngelo, K. Stevenson, D. Neuberg, L. Silverman +15 more
201543 citations
Semantic Scholar
Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-&bgr; tyrosine kinase inhibitor, in patients with recurrent glioblastoma
T. Batchelor, E. Gerstner, Xiao-Bu Ye, S. Desideri +7 more
2016Neuro-Oncology41 citations Open access
Semantic Scholar
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia
A. Fathi, Seth A. Wander, T. Blonquist, A. Brunner +22 more
2016Haematologica39 citations Open access
Semantic Scholar
A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
B. Holkova, J. Supko, M. Ames, J. Reid +14 more
2013Clinical Cancer Research39 citations Open access
Semantic Scholar
Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer.
B. Wolpin, K. Ng, A. Zhu, T. Abrams +15 more
2013The Oncologist37 citations Open access
Semantic Scholar
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
L. Spring, Shealagh Clark, Tian-Yu Li, S. Goel +10 more
2021npj Breast Cancer35 citations Open access
Semantic Scholar
Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system
N. McDannold, Yong-Zhi Zhang, J. Supko, Chanikarn Power +4 more
2020Scientific Reports35 citations Open access
Semantic Scholar
A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
K. Blum, J. Supko, M. Maris, I. Flinn +9 more
2022Cancer Research Communications33 citations Open access
Semantic Scholar
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours
P. Konstantinopoulos, Su-Chun Cheng, J. Supko, M. Polak +19 more
2021British Journal of Cancer33 citations Open access
Semantic Scholar
ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM)
N. Raje, D. Vogl, P. Hari, S. Jagannath +7 more
201333 citations
Semantic Scholar
Baseline Requirements for Novel Agents Being Considered for Phase II/III Brain Cancer Efficacy Trials:Conclusions from the Adult Brain Tumor Consortium's First Workshop on CNS Drug Delivery.
Stuart A. Grossman, Carlos G. Romo, M. Rudek, J. Supko +12 more
2020Neuro-Oncology32 citations Open access
Semantic Scholar
Phase I adult brain tumor consortium (ABTC) trial of ABT-888 (veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK) data.
L. Kleinberg, J. Supko, T. Mikkelsen, J. Blakeley +7 more
201331 citations
Semantic Scholar
Targeting Constitutively Active STAT3 in Chronic Lymphocytic Leukemia: A Clinical Trial of the STAT3 Inhibitor Pyrimethamine with Pharmacodynamic Analyses
Jennifer R. Brown, S. Walker, Lisa N. Heppler, S. Tyekucheva +16 more
2020American journal of hematology/oncology30 citations Open access
Semantic Scholar
Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study
N. Raje, P. Hari, D. Vogl, S. Jagannath +6 more
201227 citations
Semantic Scholar
A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies.
A. Langleben, J. Supko, S. Hotte, G. Batist +8 more
201326 citations
Semantic Scholar
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
L. Duska, C. Krasner, D. O'Malley, J. Hays +10 more
2020Gynecologic Oncology24 citations
Semantic Scholar
Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors
V. Abramson, J. Supko, T. Ballinger, J. Cleary +8 more
2016Clinical Cancer Research24 citations Open access
Semantic Scholar
A phase II trial of oral gimatecan for recurrent glioblastoma
Jethro L. Hu, P. Wen, L. Abrey, C. Fadul +4 more
2012Journal of Neuro-Oncology24 citations
Semantic Scholar
Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study)
N. Raje, W. Bensinger, Craig E. Cole, S. Lonial +15 more
201523 citations
Semantic Scholar
Phase 1 study of N1,N11-diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma
L. Goyal, J. Supko, J. Berlin, L. Blaszkowsky +12 more
2013Cancer Chemotherapy and Pharmacology23 citations
Semantic Scholar
A phase I extension study of BBI608, a first-in-class cancer stem cell (CSC) inhibitor, in patients with advanced solid tumors.
D. Jonker, J. Stephenson, W. Edenfield, J. Supko +6 more
201421 citations
Semantic Scholar
Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors
K. Do, Geraldine O'Sullivan Coyne, J. Hays, J. Supko +15 more
2020Cancer Chemotherapy and Pharmacology19 citations Open access
Semantic Scholar
Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combonation with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study)
Andrew J. Yee, W. Bensinger, P. Voorhees, J. Berdeja +7 more
201519 citations
Semantic Scholar
Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM)
D. Vogl, N. Raje, P. Hari, Simon S. Jones +8 more
201419 citations
Semantic Scholar
Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study of Concurrent Enzalutamide and Crizotinib
Abhishek Tripathi, J. Supko, K. Gray, Z. Melnick +11 more
2020Clinical Cancer Research18 citations Open access
Semantic Scholar
Randomized Study of Pegasparagase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001
L. Silverman, T. Blonquist, S. Hunt, S. Kay-Green +19 more
201617 citations
Semantic Scholar
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
Jennifer R. Brown, B. Messmer, L. Werner, M. Davids +15 more
2013Haematologica15 citations Open access
Semantic Scholar
Multimodal platform for assessing drug distribution and response in clinical trials.
B. Lopez, Ishwar N. Kohale, Z. Du, I. Korsunsky +24 more
2021Neuro-Oncology14 citations Open access
Semantic Scholar
Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC).
S. Wander, D. Juric, J. Supko, D. Micalizzi +13 more
202014 citations
Semantic Scholar
Abstract CT047: Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors
G. Shapiro, K. Do, S. Tolaney, J. Hilton +17 more
201711 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Xiao-Bu Ye×8
Invite
Xiao-Bu Ye — researcher profile on SciRah
S. Grossman×8
Invite
S. Grossman — researcher profile on SciRah
D. Neuberg×8
Invite
D. Neuberg — researcher profile on SciRah
G. Shapiro×7
Invite
G. Shapiro — researcher profile on SciRah

×7

Invite

N. Raje — researcher profile on SciRah

Simon S. Jones×7

Invite

Simon S. Jones — researcher profile on SciRah

Invite

C. Wheeler — researcher profile on SciRah

Invite

S. Desideri — researcher profile on SciRah

L. Silverman×6

Invite

L. Silverman — researcher profile on SciRah

Invite

S. Sallan — researcher profile on SciRah

P. Richardson×6

Invite

P. Richardson — researcher profile on SciRah

K. Stevenson×5

Invite

K. Stevenson — researcher profile on SciRah